These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 9226103

  • 1. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD, Müller TH.
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [Abstract] [Full Text] [Related]

  • 2. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2.
    Takiguchi Y, Wada K, Nakashima M.
    Thromb Haemost; 1992 Oct 05; 68(4):460-3. PubMed ID: 1448780
    [Abstract] [Full Text] [Related]

  • 4. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
    Kawano KI, Hokamura K, Kondo K, Ikeda Y, Suzuki Y, Umemura K.
    Eur J Pharmacol; 2001 Apr 13; 417(3):217-22. PubMed ID: 11334853
    [Abstract] [Full Text] [Related]

  • 5. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
    Horie S, Yamada M, Satoh M, Noritake S, Hiraishi S, Kizaki K, Kurusu O, Nakahara T, Ishii H, Kazama M.
    Biol Pharm Bull; 1997 Jun 13; 20(6):625-31. PubMed ID: 9212979
    [Abstract] [Full Text] [Related]

  • 6. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS, Wharton KA, White BP, Lumley P.
    Br J Pharmacol; 1991 Feb 13; 102(2):497-505. PubMed ID: 1826620
    [Abstract] [Full Text] [Related]

  • 7. Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.
    De La Cruz JP, Villalobos MA, Escalante R, Guerrero A, Arrebola MM, Sánchez de La Cuesta F.
    Br J Pharmacol; 2002 Dec 13; 137(7):1082-8. PubMed ID: 12429581
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G, Hemans C, Van de Water A, Xhonneux R, Wouters L, Van Ammel K, De Clerck F.
    Circ Res; 1991 Aug 13; 69(2):313-24. PubMed ID: 1830517
    [Abstract] [Full Text] [Related]

  • 9. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
    Matsuno H, Uematsu T, Umemura K, Takiguchi Y, Wada K, Nakashima M.
    Br J Pharmacol; 1992 Jul 13; 106(3):533-8. PubMed ID: 1387025
    [Abstract] [Full Text] [Related]

  • 10. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep 13; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 11. Redirection of arachidonic acid metabolism by ICI D1542: effects on thrombus formation in the coronary artery of the anaesthetized dog.
    McAuliffe SJ, Moors JA, Snow HM, Wayne M, Jessup R.
    Br J Pharmacol; 1993 Apr 13; 108(4):901-6. PubMed ID: 8485629
    [Abstract] [Full Text] [Related]

  • 12. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
    Takiguchi Y, Asai F, Wada K, Nakashima M.
    Thromb Haemost; 1995 Apr 13; 73(4):683-8. PubMed ID: 7495079
    [Abstract] [Full Text] [Related]

  • 13. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
    Olson RW, Dotson R, Mathis J, Cohen DS, Webb RL.
    Eur J Pharmacol; 1993 May 12; 236(1):75-87. PubMed ID: 8319746
    [Abstract] [Full Text] [Related]

  • 14. Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.
    McAuliffe SJ, Moors JA, Jones HB.
    Br J Pharmacol; 1994 May 12; 112(1):272-6. PubMed ID: 8032650
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F, Colombo M, Pierucci L, Volpi D, Dho L, Ukmar G, Rosa B, Salvati P.
    Drugs Exp Clin Res; 1993 May 12; 19(6):249-60. PubMed ID: 8013268
    [Abstract] [Full Text] [Related]

  • 16. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ, Smith CB, Rosenthal G, Lucchesi BR.
    J Pharmacol Exp Ther; 1986 Aug 12; 238(2):497-501. PubMed ID: 3735129
    [Abstract] [Full Text] [Related]

  • 17. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
    Brownlie RP, Brownrigg NJ, Butcher HM, Garcia R, Jessup R, Lee VJ, Tunstall S, Wayne MG.
    J Pharm Pharmacol; 1997 Feb 12; 49(2):187-94. PubMed ID: 9055193
    [Abstract] [Full Text] [Related]

  • 18. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PA.
    Thromb Haemost; 1989 Feb 28; 61(1):43-9. PubMed ID: 2526385
    [Abstract] [Full Text] [Related]

  • 19. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P, Rosolowsky M, Yao SK, McNatt J, De Clerck F, Buja LM, Willerson JT.
    J Clin Invest; 1990 Oct 28; 86(4):1095-102. PubMed ID: 2145320
    [Abstract] [Full Text] [Related]

  • 20. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.
    Yao SK, Ober JC, McNatt J, Benedict CR, Rosolowsky M, Anderson HV, Cui K, Maffrand JP, Campbell WB, Buja LM.
    Circ Res; 1992 Jan 28; 70(1):39-48. PubMed ID: 1727687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.